Search the GHTC website

Global health R&D delivers for Florida

US government investment in global health R&D has delivered

Amount
$322.2 million
to Florida research institutions
Jobs
5,100+ new jobs
for Florida
Florida's top USG-funded global health R&D institutions

Florida's top USG-funded global health R&D institutions

University of Miami (including the Miller School of Medicine)
$74.4 million
University of Florida
$74.2 million
University of South Florida
$38.9 million
University of Central Florida
$35.5 million
Ridgeback Biotherapeutics
$33 million
Florida State University
$19 million
Florida International University
$12 million
Vaccine and Gene Therapy Institute of Florida*
$6.4 million
Alchem Laboratories
$5.3 million
Florida Atlantic University
$4.3 million
Aviana Molecular Technologies LLC
$3.4 million
Emmune Inc.
$2.8 million
Foundation for Applied Molecular Evolution
$2.3 million
Nova Southeastern University
$1.7 million
Medosome Biotec LLC
$1.6 million
Quorum Innovations LLC
$1.3 million
Firebird Biomolecular Sciences LLC
$1.2 million
Ology Bioservices (formerly Nanotherapeutics)
$788 thousand
Z-Quick*
$693 thousand
Moffitt Cancer Center
$578 thousand
Discidium Biosciences LLC
$483 thousand
Morphogenesis
$432 thousand
NanoEngineering Corp.
$343 thousand
Charlot Biosciences (CBio)
$323 thousand
Stinginn LLC
$300 thousand
Lifetime Omics
$299 thousand
Ross University
$279 thousand
Smart Biomolecules
$278 thousand
ILiAD Biotechnologies LLC
$165 thousand

Florida's top areas of global health R&D by USG funding

9.2%
COVID-19
7.7%
Diarrheal diseases
10.5%
Flioviral diseases (including Ebola, Marburg)
22.9%
HIV/AIDS
17.2%
Malaria
6.5%
Neglected tropical diseases
Dengue
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Snakbite envenoming
3%
Reproductive health
13.4%
Tuberculosis
2%
Zika
7.6%
Other
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Chikungunya
Henipaviral diseases (including Nipah)
Hepatitis B
Hepatitis C
Multi-disease/health area R&D
Salmonella infections
Global health R&D at work in Florida

University of Florida (UF) scientists are studying how mosquito species in Florida spread both the Zika and chikungunya viruses. While the former is well known for causing the 2015 epidemic, the latter virus, which occurs mostly in Africa, Asia, and Central and South America, arrived in the Caribbean several years ago, and since then, hundreds of cases have been diagnosed in Florida, including a dozen locally transmitted cases. The virus causes fever, headaches, muscle and joint pain, and, in some cases, chronic rheumatoid arthritis. These studies will help scientists model disease transmission to better control future outbreaks. UF also houses and coleads the US Centers for Disease Control and Prevention’s Southeastern Center of Excellence in Vector-Borne Diseases, which helps advance research programs across the region to inform the prevention and control of vector-borne diseases.

Footnotes
  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: CDC/James Gathany